Abstract

Comparative quantitative evaluation of estrogen receptors β (ERβ) expression is performed by the immunofluorescence method using flow cytometry in the ovarian cancer cell lines COLO-704, OVCAR-3, EFO-21, and SK-OV-3, as well as the breast cancer cell line MCF-7. A high level of ERβ expression (88–91%) is revealed in all the cell cultures investigated, and significant differences were observed in the intensity of the marker’s expression between ovarian cancer cell cultures (in OVCAR-3, EFO-21, and SK-OV-3 they are higher than in COLO-704 cells by factors of 1.6, 2.3, and 3.5, respectively). Moreover, the intensity of ERβ expression was significantly higher in SK-OV-3, EFO-21, and OVCAR-3 than in MCF-7 cells: in 2.7; 1.4 and 1.9 times, respectively. The authors suggest that in contrast to breast cancer patients, ERβ rather than ERα could be the main target for antiestrogens in ovarian cancer patients. The revealed differences in the ERβ expression in a number of widely used ovarian cancer cell cultures lead us to recommend them for further fundamental research on ERβ to study the biological effects of antiestrogens.

中文翻译：

---

卵巢癌和乳腺癌细胞系中雌激素受体β表达的比较免疫荧光分析

摘要

使用流式细胞术，通过免疫荧光法对卵巢癌细胞系COLO-704，OVCAR-3，EFO-21和SK-OV-3以及乳房中的雌激素受体β（ERβ）表达进行定量比较评估癌细胞系MCF-7。在所有研究的细胞培养物中均显示出高水平的ERβ表达（88–91％），并且在卵巢癌细胞培养物中（在OVCAR-3，EFO-21和SK中）标志物的表达强度观察到了显着差异。 -OV-3分别比COLO-704细胞高1.6、2.3和3.5倍）。此外，与MCF-7细胞相比，SK-OV-3，EFO-21和OVCAR-3中的ERβ表达强度显着更高：在2.7中；在2.7中。分别是1.4和1.9倍。作者建议，与乳腺癌患者相比，ERβ而不是ERα可能是卵巢癌患者抗雌激素的主要靶标。在许多广泛使用的卵巢癌细胞培养物中，ERβ表达的显着差异促使我们推荐它们用于ERβ的进一步基础研究，以研究抗雌激素的生物学作用。